Intramedullary Osteosarcoma Treatment Market Size & Share, by Treatment Type (Chemotherapy, Combination Therapy, Targeted Therapy); Distribution Channels (Hospital Pharmacies, University Hospitals Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5851
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Intramedullary Osteosarcoma Treatment Market size is anticipated to reach USD 1 Billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of intramedullary osteosarcoma treatment was over USD 513 Million. Intramural osteosarcoma, also known as osteogenic sarcoma, is the most common type of bone cancer and develops in the cells that make new bone. For instance, approximately 3,970 new cases were detected in adult Americans in 2023. Osteosarcoma can affect any bone in the body, although it most commonly affects the long bones, such as the hands and legs. Signs and symptoms of osteosarcoma include regional bone pain and edema. Throughout the projection period, there will likely be a greater need for intramedullary osteosarcoma treatment due to the high incidence of osteosarcoma around the world.

Moreover, by raising the proportion of cases identified at an early stage, early detection activities such as screening programs for high-risk persons or those with predisposing characteristics can support the market's overall expansion. Additionally, early discovery makes it possible to intervene sooner, which improves treatment results and raises survival rates. Therefore, these factors are propelling the growth of the intramedullary osteosarcoma treatment market.


Intramedullary Osteosarcoma Treatment Market
Get more information on this report: Request Free Sample PDF

Intramedullary Osteosarcoma Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Awareness Regarding the Disease - As awareness grows, so does the need for more sophisticated treatment choices, which drives up funding for the study and creation of novel treatments and technological solutions for intramedullary osteosarcoma. For instance, the Bone Cancer Awareness Initiative, a 100-day program aims to reach all general practitioners (GP practices), medical students, radiology departments, muscular skeletal physiotherapists, and pharmacies in the UK. It culminates in Bone Cancer Awareness Week (5-11 October). This initiative equips them—for the first time—with the information and specific instruments needed to recognize a possible case of primary bone cancer and to confirm or rule out a diagnosis. Therefore, public health awareness campaigns are also escalating the growth of the market.
  • Growing Initiatives for R&D Activities by Governments Worldwide – The market expansion can be attributed to the increased government funding for R&D activities for various diseases and treatments. Also, governments in various nations are highly investing in the healthcare sector which is also accelerating the market growth. For instance, in 2021, 73% of healthcare spending in various nations was funded by public sources on average. In countries like Norway, Sweden, and Denmark where government financing schemes are the primary source of funding, government transfers account for at least 85% of healthcare spending. The majority of public funding in other nations, like Slovenia or Germany, relates to social insurance contributions that businesses and employees are required to provide.Therefore, this factor is expected to drive the growth of the intramedullary osteosarcoma treatment market.
  • Surge in Technological Advancements – The advent of advanced imaging methods like MRIs, CT scans, and PET scans as a result of technological breakthroughs has made it possible to identify intramedullary osteosarcoma earlier and with more accuracy. Additionally, advancements in robotic surgery and computer-assisted navigation have improved the efficacy and precision of tumor excision while reducing harm to adjacent healthy tissue. As per a report, between 2012 and 2018, the proportion of surgical procedures in the US carried out using robotic technology rose from 0% to 19%. Furthermore, the application of personalized medicine techniques in the management of intramedullary osteosarcoma has been made easier by technological developments.


  • Toxicity of Chemotherapy – Treatment for intramedullary osteosarcoma with chemotherapy regimens has the potential to cause serious adverse effects, such as myelosuppression, gastrointestinal distress, neuropathy, and cardiotoxicity. Healthcare practitioners face a clinical challenge in managing these side effects while maintaining treatment efficacy. Therefore, this factor may hinder the growth of the market throughout the projected period.
  • High Costs of Treatment may Hamper the Market Growth
  • Surgical Resection of Intramedullary Osteosarcoma can be Technically Challenging Which May Impede the Growth of the Market

Intramedullary Osteosarcoma Treatment Market: Key Insights

Base Year


Forecast Year



~ 5%

Base Year Market Size (2023)

 ~ USD 513 Million

Forecast Year Market Size (2036)

 ~ USD 1 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Intramedullary Osteosarcoma Treatment Segmentation

Treatment Type (Chemotherapy, Combination Therapy, Targeted Therapy)

The targeted therapy segment in the intramedullary osteosarcoma treatment market is expected to hold a share of 44% during the forecast period. These therapies are designed to specifically target molecular alterations or pathways that drive cancer growth, making them more precise and potentially less toxic than traditional chemotherapy. Also, ongoing research and clinical trials are evaluating the safety and efficacy of targeted therapies in intramedullary osteosarcoma. For instance, Topline results from the LIBRETTO-431 study, which compared Retevmo to platinum-based chemotherapy plus pemetrexed, with or without pembrolizumab, as an initial treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that was rearranged during transfection (RET) were released by Eli Lilly and Company. With a statistically significant and clinically relevant improvement in progression-free survival (PFS), the trial achieved its primary aim. Furthermore, advances in molecular profiling technologies and understanding of the genetic and molecular mechanisms underlying osteosarcoma have led to the identification of potential targets for therapy.

Distribution Channels (Hospital Pharmacies, University Hospitals Pharmacies)

The hospital pharmacies segment in the intramedullary osteosarcoma treatment market is anticipated to hold the largest share of 54% during the forecast period. The availability of specific drugs and chemotherapeutic treatments for the treatment of intramedullary osteosarcoma is responsible for the rise. In addition, there is an increasing need for healthcare services, particularly prescription drugs, as the population ages and grows. As per a report, 771 million individuals worldwide were 65 years of age or older in 2022, making up about 10% of the world's population. With its steady growth, this market is predicted to reach sixteen percent by the year 2050. Hospital pharmacies are essential to the general expansion of the healthcare sector because they provide patients with pharmaceutical care inside hospital settings. Furthermore, hospital pharmacies are growing to fulfill these standards and implementing cutting-edge technologies like automated dispensing systems and electronic medication records in response to the growing emphasis on medication management and adherence. The provision of specialty services including compounding, oncology pharmacy, and clinical pharmacy services is another factor fueling the market's expansion.

Our in-depth analysis of the global market includes the following segments:

          Treatment Type

  • Chemotherapy
  • Combination Therapy
  • Targeted Therapy


  • Hospital Pharmacies
  • University Hospitals Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Intramedullary Osteosarcoma Treatment Industry - Regional Synopsis

North American Market Forecast

The North American intramedullary osteosarcoma treatment market is anticipated to hold a share of 37% during the forecast period. It is expected that the region will increase its market share in the future because there are multiple clinical studies for bone cancer treatments underway, most of which are in the United States. Numerous researchers are testing new chemotherapy treatments. Scholars are already contemplating innovative uses for the assortment of presently approved medications. For example, scientists are investigating whether mixing bone cement and the bisphosphonate zoledronic acid (Zometa), which is used to fill the gap left by a giant cell tumor, can reduce the risk of the tumor growing back in that region. Throughout the forecast period, these factors are expected to boost the market.

European Market Statistics

intramedullary osteosarcoma treatment market in Europe is expected to grow with the second-largest share of 27% by the end of 2036. While osteosarcoma is a rare cancer, its incidence has been gradually increasing, contributing to the growth of the market. The region has stringent regulatory standards for drug approval and patient safety. Adoption of intramedullary osteosarcoma treatment is becoming more common in industrialized nations due to rising government spending on healthcare. A potential driver of the intramedullary osteosarcoma market's expansion may be the disease's rising prevalence rate.

Research Nester
Intramedullary Osteosarcoma Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Intramedullary Osteosarcoma Treatment Landscape

    • OS Therapies
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • RefleXion
    • Novartis International AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Baxter
    • Aurobindo Pharma
    • Hikma Pharmaceuticals PLC


In The News

  • October 2021 - OS Therapies, a research and clinical-stage biopharmaceutical company announced today the dosing of the "First Patient In" for its lead OST-HER2 (OST31-164) program in a potentially pivotal Phase IIb clinical trial. OST-HER2 has already received Fast-Track and Orphan Designation from the EMA and FDA. The nationwide open-label trial will enroll 39 to 45 Osteosarcoma patients whose cancer has metastasized to the lungs and has been surgically resected.
  • February 2023 - The U.S. Food and Drug Administration (FDA) has approved the first marketing authorization for RefleXion Medical's SCINTIXTM biology-guided radiation, a novel treatment that can be used for both early- and late-stage tumors. The CEO and co-founder of the company will be speaking live on the company's website about the groundbreaking potential of SCINTIX therapy for the treatment of cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5851
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing awareness regarding the disease, growing initiatives for R&D activities by governments worldwide, and a surge in technological advancements are the major factors driving the growth of the intramedullary osteosarcoma treatment market.

The market size of intramedullary osteosarcoma treatment is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024-2036.

The major players in the market are OS Therapies, RefleXion, Novartis International AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson Services, Inc., Baxter, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and others.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Intramedullary Osteosarcoma Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying